The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I'm really not sure we're speaking the same language
I'm not knocking my investment.... there isn't a value or market yet ?
The pink slip price is down to less than half ..... whats good? Why?
Give me some positives? I'll see positives 1. When the market opens and 2. When we see some communication regarding accustem
This was hyped to get everyone to buy tils to get free accustem pushing the price up. No one did this to hold free shares they can do nothing with
Accustem has massive potential but waiting a year in no man's land .... gives investors nothing and gives competition time to develop or improve competitive products. We're losing valuable time and after nearly a year no nothing
Unless you no more than anyone else not just hot air throw away comments
Chuggley,
Exactly the dumb response expected from someone who knocks their own Investment, for what reason is very clear.
Oldapache. Read again. I don't say I've seen it all. I said I've seen it
Also. Just because I've seen it doesn't mean what I saw at the time
Just what's happening lately ... which is well after getting into this originally
But I guess your trying to be clever. Unsuccessfully
Chuggley,
If you've seen it all before, why would you get involved?
Just asking.
Chuggley
No point emailing them ! They do not ever reply ! Investor Relations are shambolic !
And why wouldn't it go down. No new. No communication why would people buy
And I've seen this before. Let a price drop so they're happy getting a firesale price.
To be honest it's criminal and negligent to treat shareholders this way after promoting the big buy tils get accustem free. Driving tils price towards £3
People always blame nda for gagging and silence but are rarely correct
Does anyone have an email address we can contact?
I recall about 18 months back a load of talk from the board re 5 NDAs . Was that all bull or will we find truth in it. If so, soon please !!
I guess the funding dilution/price will depend on the outcome of the Foralumab POC/Covid trial in Brazil (Phase II). The FDA may also look more kindly on any approvals due to being a Nasdaq only listed company - America first etc. (I'm sure they don't do that!!!!!)
BB
BB,
Not looking today great today but I think we may be turning a corner as per next Thursday. Im expecting news on start of trials by end oct. Do you concur? More importantly what value do you suspect that will add to SP on nas? Perhaps futile speculating but interesting none the less. Also Im expecting a placing some point next year so expecting Dr K to start the hype train soon. I think they will look to get the funding between £1.20-£1.50 give or take.. what are your thoughts? GLA
SK,
Ouch indeed.. ive just seen that! Looks like time to steal a few hundred pounds from somewhere and average down more :(. Endless averaging down!! Ok keep calm!! Wusa Wusa!
Shiraz
OUCH have you seen the latest Accustem pink sheet price ? $0.19
it is down a massive 26.92% -0.070 Today ! Investors are becoming impatient !
StarKnight
Davey
I am also sorry to hear of your loss, the sooner this essay gets to market the more peoples suffering can be better diagnosed roll on
DCR
Ditto - SK39 comment.
BB
Davey.. great post.. shows some human side of the work these guys are doing which is one of the reasons I have been invested for the last few years and will be for the long term. Sorry to hear about your loss,
All the best wishes
I agree that they could be negotiating the sale of Accustem's assets in StemprintER and Spare but you would have thought they'd have secured a deal by now. Anyway one day I'm sure something will happen. My twin 21 year old daughters mother died of BRAC2+ breast cancer in 2008 so they will directly benefit from a better prognosis test that the current one, so I have a vested interest in this, apart from being an Investor.
Hope your right SK,
I bought 10k worth accustem on pink sheets thinking I got a bargain.. 3k down in it already… ah well one to lock away for next few years I guess..
On a brighter note cant wait for next thursday.. surely the start of trials is imminent now and GC has put his money where his mouth is last few weeks so hoping for some good news imminently. GLA
A possible cause for the delay and silence could be that the BOD are in negotiations with a big pharma for a buyout of Accustem and due to NDA’s they cannot state anything
Still complete silence and lack of any communication or progress updates from Accustem. No surprise given the Company's complete disregard for shareholders.